相关实验视频

Updated: Jun 14, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

长非编码RNAABHD11-AS1与恶性瘤预后之间的关联:一个元分析

Guangyao Lin¹, Tao Ye², Jing Wang³

¹Department of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200030, China.

|September 2, 2024

概括

长非编码RNAABHD11-AS1表达的升高与较差的癌症结果有关,包括转移和晚期瘤阶段. 这表明ABHD11-AS1可能成为癌症查和预后预测的宝贵生物标志物.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物标志物发现发现

背景情况:

长非编码RNAABHD11-AS1与瘤发生有关,具有作为癌症生物标志物和治疗点的潜力.
之前关于ABHD11-AS1在恶性瘤中的作用的研究由于样本大小有限而产生了相互矛盾的结果.
这一元分析旨在整合现有数据,以澄清ABHD11-AS1与各种人类癌症之间的关联.

研究的目的:

量化评估ABHD11-AS1表达与人类恶性瘤的发展和进展之间的关系.
评估ABHD11-AS1作为癌症预后的潜在预测生物标志物.

主要方法:

在8个数据库中进行了系统的文献搜索,截至2024年1月1日.
分析利用几率比率 (ORs) 和危险比率 (HRs) 与95%的置信区间 (CI) 来确定显著性.
进行了子组,敏感性,GEPIA2021和UCSC Xena数据库分析,以确保结果的可靠性和稳定性.

主要成果:

分析包括14项研究,涉及8种癌症类型的1215例恶性瘤病例.
增加的ABHD11-AS1表达与淋巴结转移 (OR=2.73),晚期瘤阶段 (OR=3.14) 和不利的整体存活率 (HR=1.81) 显著相关.
外部验证证实8种恶性瘤中ABHD11-AS1升高及其与预后不佳相关 (PFI,DFI,DSS,OS).

结论:

升高的ABHD11-AS1表达与较差的癌症预后密切相关.
作为癌症查和预测患者结果的生物标志物,ABHD11-AS1显示出前景.
需要进一步的大规模,多中心的研究与标准化的协议来验证这些发现.

关键词:

这种LncRNA是ABHD11-AS1的.恶性瘤是一种恶性瘤.进行元分析分析.预测预后预测预测审查审查审查审查

更多相关视频

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Non-LTR Retrotransposons

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...

RNA Splicing

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...